371 related articles for article (PubMed ID: 20230412)
1. Monitoring heparin anticoagulation in the acute phase response.
Uprichard J; Manning RA; Laffan MA
Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
[TBL] [Abstract][Full Text] [Related]
2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
6. The APTT response of pregnant plasma to unfractionated heparin.
Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
[TBL] [Abstract][Full Text] [Related]
7. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of unfractionated heparin therapy in children: time for change?
Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
[TBL] [Abstract][Full Text] [Related]
9. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
10. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
[TBL] [Abstract][Full Text] [Related]
11. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
Clark NP; Delate T; Cleary SJ; Witt DM
Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
[TBL] [Abstract][Full Text] [Related]
12. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
13. Dalteparin dose-dependently increases ROTEM(®) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study.
Feuring M; Wehling M; Schultz A
Clin Exp Pharmacol Physiol; 2011 Nov; 38(11):783-6. PubMed ID: 21883380
[TBL] [Abstract][Full Text] [Related]
14. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
15. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
16. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
17. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
18. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
19. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
20. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
